Sagimet’s denifanstat delivered significant improvements in disease activity and fibrosis for patients with metabolic dysfunction-associated steatohepatitis.
Injecting lung stem cells into the bloodstream of mice with idiopathic pulmonary fibrosis improved their lung function, setting the stage for human trials.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?